HRP20231517T1 - Postupci liječenja autoimunih mikrovaskularnih poremećaja - Google Patents
Postupci liječenja autoimunih mikrovaskularnih poremećaja Download PDFInfo
- Publication number
- HRP20231517T1 HRP20231517T1 HRP20231517TT HRP20231517T HRP20231517T1 HR P20231517 T1 HRP20231517 T1 HR P20231517T1 HR P20231517T T HRP20231517T T HR P20231517TT HR P20231517 T HRP20231517 T HR P20231517T HR P20231517 T1 HRP20231517 T1 HR P20231517T1
- Authority
- HR
- Croatia
- Prior art keywords
- diosmetin
- pharmaceutically acceptable
- acceptable salt
- diosmin
- active ingredient
- Prior art date
Links
- 230000001363 autoimmune Effects 0.000 title 1
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 claims 19
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 claims 19
- 229960001876 diosmetin Drugs 0.000 claims 19
- 235000015428 diosmetin Nutrition 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 claims 15
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 claims 15
- 229960004352 diosmin Drugs 0.000 claims 15
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 claims 15
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims 15
- 239000004480 active ingredient Substances 0.000 claims 13
- 208000025865 Ulcer Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 231100000397 ulcer Toxicity 0.000 claims 3
- 235000005881 Calendula officinalis Nutrition 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 241000736851 Tagetes Species 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 201000002829 CREST Syndrome Diseases 0.000 claims 1
- 201000003066 Diffuse Scleroderma Diseases 0.000 claims 1
- 208000024140 Limited cutaneous systemic sclerosis Diseases 0.000 claims 1
- 208000024136 Limited systemic sclerosis Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 206010027982 Morphoea Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (13)
1. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u postupku liječenja ulkusa na prsima kod subjekta sa sistemnom sklerozom, naznačeni time što se liječenje sastoji u oralnoj primjeni terapijski djelotvorne količine diosmina ili diosmetina, ili njihove farmaceutski prihvatljive soli, na navedenom subjektu kroz terapijski djelotvoran vremenski period.
2. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačeni time što subjekt ima mikrovaskulitis u terminalnim arterijskim krvnim žilama ili kapilarama.
3. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što subjekt ima nevenski mikrovaskulitis.
4. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što subjekt ima nevenski mikrovaskulitis u terminalnim arterijskim krvnim žilama ili kapilarama.
5. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što navedeni subjekt ima sklerotic stanje, kojeg se bira između difuzne sistemne skleroze, ograničene sistemne skleroze, te morfeje.
6. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što navedeni subjekt ima sindrom CREST.
7. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što navedeni subjekt ima jedan ili više ulkusa na prsima, koji su posljedica ishemije prstiju i sekundarnog Raynaudovog fenomena.
8. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što navedeni subjekt ima jedan ili više ulkusa na prsima, koji su posljedica ishemije uzrokovane kombinacijom mikrovaskularne bolesti i stvarnog gubitka kapilara povezanog s ishemijom uzrokovanom vazospazmom povezanim sa sekundarnim Raynaudovim fenomenom.
9. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se navedena terapijska djelotvorna količina kreće od 300 do 5000 mg diosmina, ili njegove farmaceutski prihvatljive soli, koju se svakodnevno primjenjuje oralno na subjektu.
10. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se navedena terapijska djelotvorna količina kreće od 150 do 2500 mg diosmetina, izborno od 200 do 1000 mg diosmetina, ili njegove farmaceutski prihvatljive soli, koju se svakodnevno primjenjuje oralno na subjektu.
11. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se navedena terapijska djelotvorna količina kreće od 400 do 2000 mg diosmetina, ili njegove farmaceutski prihvatljive soli, koju se svakodnevno primjenjuje oralno na subjektu.
12. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se navedena terapijska djelotvorna količina kreće od 800 do 1200 mg diosmetina, ili njegove farmaceutski prihvatljive soli, koju se svakodnevno primjenjuje oralno na subjektu.
13. Diosmin ili diosmetin, ili njihova farmaceutski prihvatljiva sol, koji služe kao jedini aktivni sastojak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što se navedena terapijska djelotvorna količina kreće od 400 do 600 mg diosmetina, ili njegove farmaceutski prihvatljive soli, koju se svakodnevno primjenjuje oralno na subjektu.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762534237P | 2017-07-19 | 2017-07-19 | |
EP18836058.0A EP3654965B1 (en) | 2017-07-19 | 2018-07-18 | Methods of treating autoimmune microvascular disorders |
PCT/US2018/042573 WO2019018455A1 (en) | 2017-07-19 | 2018-07-18 | METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231517T1 true HRP20231517T1 (hr) | 2024-03-01 |
Family
ID=65016682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231517TT HRP20231517T1 (hr) | 2017-07-19 | 2018-07-18 | Postupci liječenja autoimunih mikrovaskularnih poremećaja |
Country Status (12)
Country | Link |
---|---|
US (2) | US11278517B2 (hr) |
EP (2) | EP3654965B1 (hr) |
JP (1) | JP7237962B2 (hr) |
KR (1) | KR20200051579A (hr) |
CN (1) | CN111065389B (hr) |
AU (1) | AU2018304208B2 (hr) |
CA (1) | CA3069921C (hr) |
ES (1) | ES2957742T3 (hr) |
HR (1) | HRP20231517T1 (hr) |
MX (1) | MX2020000625A (hr) |
PL (1) | PL3654965T3 (hr) |
WO (1) | WO2019018455A1 (hr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306300A (zh) * | 2022-01-04 | 2022-04-12 | 上海交通大学医学院附属仁济医院 | 一种香叶木素的用途及其动物模型的建立方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1288257B1 (it) * | 1996-11-29 | 1998-09-11 | Paoli Ambrosi Gianfranco De | Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico |
WO2004017956A1 (en) | 2002-08-20 | 2004-03-04 | Protemix Corporation Limited | Dosage forms and related therapies |
FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015153648A1 (en) | 2014-03-31 | 2015-10-08 | Ingredients By Nature | Flavonoid compositions and uses thereof |
-
2018
- 2018-07-18 US US16/632,032 patent/US11278517B2/en active Active
- 2018-07-18 CN CN201880053173.6A patent/CN111065389B/zh active Active
- 2018-07-18 KR KR1020207003115A patent/KR20200051579A/ko not_active Application Discontinuation
- 2018-07-18 EP EP18836058.0A patent/EP3654965B1/en active Active
- 2018-07-18 AU AU2018304208A patent/AU2018304208B2/en active Active
- 2018-07-18 ES ES18836058T patent/ES2957742T3/es active Active
- 2018-07-18 PL PL18836058.0T patent/PL3654965T3/pl unknown
- 2018-07-18 HR HRP20231517TT patent/HRP20231517T1/hr unknown
- 2018-07-18 WO PCT/US2018/042573 patent/WO2019018455A1/en unknown
- 2018-07-18 EP EP23195481.9A patent/EP4269397A3/en active Pending
- 2018-07-18 JP JP2020524721A patent/JP7237962B2/ja active Active
- 2018-07-18 CA CA3069921A patent/CA3069921C/en active Active
- 2018-07-18 MX MX2020000625A patent/MX2020000625A/es unknown
-
2022
- 2022-02-14 US US17/670,609 patent/US11844777B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220168267A1 (en) | 2022-06-02 |
EP4269397A3 (en) | 2024-01-31 |
AU2018304208A1 (en) | 2020-02-13 |
US11844777B2 (en) | 2023-12-19 |
EP3654965A1 (en) | 2020-05-27 |
EP3654965B1 (en) | 2023-09-06 |
ES2957742T3 (es) | 2024-01-24 |
CA3069921A1 (en) | 2019-01-24 |
US20200147031A1 (en) | 2020-05-14 |
AU2018304208B2 (en) | 2022-03-17 |
JP7237962B2 (ja) | 2023-03-13 |
KR20200051579A (ko) | 2020-05-13 |
JP2020528454A (ja) | 2020-09-24 |
EP3654965A4 (en) | 2021-03-10 |
US11278517B2 (en) | 2022-03-22 |
PL3654965T3 (pl) | 2024-02-26 |
CN111065389A (zh) | 2020-04-24 |
CN111065389B (zh) | 2023-11-21 |
CA3069921C (en) | 2022-01-18 |
MX2020000625A (es) | 2020-09-28 |
EP4269397A2 (en) | 2023-11-01 |
WO2019018455A1 (en) | 2019-01-24 |
EP3654965C0 (en) | 2023-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
JP2016053040A5 (hr) | ||
RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
HRP20171570T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
HRP20220025T1 (hr) | Režim doziranja valbenazina za liječenje hiperkinetičkih poremećaja kretanja | |
FI3668509T3 (fi) | Menetelmä hoitaa amyotrofista lateraaliskleroosia pridopidiinilla | |
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
HRP20230935T1 (hr) | Postupci za liječenje i profilaksu hiv-a i aids-a | |
RU2015134421A (ru) | Применение левоцетиризина и монтелукаста при лечении травматических повреждений | |
JP2015537009A5 (hr) | ||
HRP20231517T1 (hr) | Postupci liječenja autoimunih mikrovaskularnih poremećaja | |
HRP20231587T1 (hr) | Kronično noćno doziranje lasmiditana radi sprječavanja migrene | |
JP2007504194A5 (hr) | ||
RU2018125252A (ru) | Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции | |
BR112015015938A2 (pt) | uso de cloridrato de fenilefrina e paracetamol, medicamento, método de tratamento de congestão das mucosas do trato respiratório superior em um humano adulto | |
HRP20171514T1 (hr) | Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt | |
HRP20230693T1 (hr) | Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti | |
EA201891860A1 (ru) | Фармацевтическая композиция пролонгированного высвобождения, содержащая цистеамин или его соли | |
JP2020528454A5 (hr) | ||
JP2017530142A5 (hr) | ||
HRP20171305T1 (hr) | Upotreba odiparcila u liječenju mukopolisaharidoze | |
RU2017129085A (ru) | Новый состав N-карбамоилметил-4-фенил-2-пирролидона | |
RU2024106929A (ru) | Применение новой терапевтической комбинации для лечения хронической венозной недостаточности |